View ValuationBlack Hawk Acquisition 将来の成長Future 基準チェック /06現在、 Black Hawk Acquisitionの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長11.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 04/14/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 03Black Hawk Acquisition Corp Receives Non-Compliance Notice from the Nasdaq Stock Market LLCOn March 31, 2026, Black Hawk Acquisition Corporation (the Company) received a notice (the MVLS Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) stating that the Company's market value of listed securities (MVLS) for the last 30 consecutive business days was less than the $50,000,000 required for continued listing on the Nasdaq Global Market under Listing Rule 5450(b)(2)(A) (the MVLS Requirement). The Company has a period of 180 calendar days, or until September 28, 2026 (the MVLS Compliance Date), to regain compliance with the MVLS Requirement. To regain compliance with the MVLS Requirement, the Company's MVLS must close at $50,000,000 or more for a minimum period of ten consecutive business days. Nasdaq may, in its discretion, require the Company to maintain the minimum MVLS for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. In the event the Company does not regain compliance with the MVLS Requirement prior to the MVLS Compliance Date, the Company will receive written notification that the Company's securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel, but there can be no assurance that the panel would grant the Company's request for continued listing. Alternatively, the Company may consider applying to transfer the listing of the Company's securities to the Nasdaq Capital Market (the Capital Market), provided that the Company then satisfies the requirements for continued listing on that market. The Company is monitoring the MVLS of its listed securities and is considering available options to regain compliance with Nasdaq's continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) or maintain compliance with other applicable Nasdaq listing requirements. The Notice does not result in the immediate delisting of the Company's class A Ordinary Shares, and the Company's Units, Rights, and Class A Ordinary Shares, will continue to trade uninterrupted on the Nasdaq Global Market under the symbols BKHAU, BKHAR, and BKHA, respectively.お知らせ • Mar 03Black Hawk Acquisition Corporation announced delayed annual 10-K filingOn 03/02/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Oct 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 10/15/2025, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 07Black Hawk Acquisition Corporation Announces Committee and Board ChangesOn April 29, 2025, Black Hawk Acquisition Corporation reported the death of Brandon Miller, a member of the Company’s board of directors and the Chairperson of the Audit Committee. On April 29, 2025, the Board appointed Daniel M. McCabe, a current member of the Board and the then Chairperson of the Compensation Committee, to serve as Chairperson of the Audit Committee. On the same day, Mr. McCabe resigned from his position as Chairperson of the Compensation Committee, and the Board appointed Terry W. Protto, a current member of the Board, to serve as Chairperson of the Compensation Committee.お知らせ • Apr 29Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million.Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million on April 26, 2025. The Transaction values Vesicor at a pre-money equity value of $70 million. Under the terms of the merge with Vesicor, resulting in Vesicor being the wholly owned subsidiary of Black Hawk, who will continue to be the listed company on the Nasdaq Stock Market and change its name to Vesicor Therapeutics. The Transaction, which has been approved unanimously by the boards of directors of both Black Hawk and Vesicor, is subject to regulatory approvals, the approvals by the shareholders of Black Hawk and Vesicor, respectively, and the satisfaction of certain other customary closing conditions, including, among others, a Form S-4 registration statement under the Securities Act of 1933, of which the proxy statement/prospectus forms a part, being declared effective by the U.S. Securities and Exchange Commission (the “SEC”), and the approval by Nasdaq of the listing application of the combined company. The Business Combination is expected to be completed by the fourth quarter of 2025. Celine & Partners, PLLC acted as legal advisor for Black Hawk Acquisition Corporation. Ogier Global Limited acted as legal advisor for Black Hawk Acquisition Corporation. PW Richter plc acted as legal advisor for Vesicor Therapeutics, Inc. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Black Hawk Acquisition は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqGM:BKHA - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数2/28/2026N/A1-1-1N/A11/30/2025N/A1-1-1N/A8/31/2025N/A2-1-1N/A5/31/2025N/A3-1-1N/A2/28/2025N/A3-1-1N/A11/30/2024N/A2-1-1N/Aアナリストによる今後の成長予測収入対貯蓄率: BKHAの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BKHAの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BKHAの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BKHAの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BKHAの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BKHAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 11:09終値2026/05/21 00:00収益2026/02/28年間収益2025/11/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Black Hawk Acquisition Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 04/14/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 03Black Hawk Acquisition Corp Receives Non-Compliance Notice from the Nasdaq Stock Market LLCOn March 31, 2026, Black Hawk Acquisition Corporation (the Company) received a notice (the MVLS Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) stating that the Company's market value of listed securities (MVLS) for the last 30 consecutive business days was less than the $50,000,000 required for continued listing on the Nasdaq Global Market under Listing Rule 5450(b)(2)(A) (the MVLS Requirement). The Company has a period of 180 calendar days, or until September 28, 2026 (the MVLS Compliance Date), to regain compliance with the MVLS Requirement. To regain compliance with the MVLS Requirement, the Company's MVLS must close at $50,000,000 or more for a minimum period of ten consecutive business days. Nasdaq may, in its discretion, require the Company to maintain the minimum MVLS for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. In the event the Company does not regain compliance with the MVLS Requirement prior to the MVLS Compliance Date, the Company will receive written notification that the Company's securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel, but there can be no assurance that the panel would grant the Company's request for continued listing. Alternatively, the Company may consider applying to transfer the listing of the Company's securities to the Nasdaq Capital Market (the Capital Market), provided that the Company then satisfies the requirements for continued listing on that market. The Company is monitoring the MVLS of its listed securities and is considering available options to regain compliance with Nasdaq's continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) or maintain compliance with other applicable Nasdaq listing requirements. The Notice does not result in the immediate delisting of the Company's class A Ordinary Shares, and the Company's Units, Rights, and Class A Ordinary Shares, will continue to trade uninterrupted on the Nasdaq Global Market under the symbols BKHAU, BKHAR, and BKHA, respectively.
お知らせ • Mar 03Black Hawk Acquisition Corporation announced delayed annual 10-K filingOn 03/02/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Oct 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 10/15/2025, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 07Black Hawk Acquisition Corporation Announces Committee and Board ChangesOn April 29, 2025, Black Hawk Acquisition Corporation reported the death of Brandon Miller, a member of the Company’s board of directors and the Chairperson of the Audit Committee. On April 29, 2025, the Board appointed Daniel M. McCabe, a current member of the Board and the then Chairperson of the Compensation Committee, to serve as Chairperson of the Audit Committee. On the same day, Mr. McCabe resigned from his position as Chairperson of the Compensation Committee, and the Board appointed Terry W. Protto, a current member of the Board, to serve as Chairperson of the Compensation Committee.
お知らせ • Apr 29Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million.Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million on April 26, 2025. The Transaction values Vesicor at a pre-money equity value of $70 million. Under the terms of the merge with Vesicor, resulting in Vesicor being the wholly owned subsidiary of Black Hawk, who will continue to be the listed company on the Nasdaq Stock Market and change its name to Vesicor Therapeutics. The Transaction, which has been approved unanimously by the boards of directors of both Black Hawk and Vesicor, is subject to regulatory approvals, the approvals by the shareholders of Black Hawk and Vesicor, respectively, and the satisfaction of certain other customary closing conditions, including, among others, a Form S-4 registration statement under the Securities Act of 1933, of which the proxy statement/prospectus forms a part, being declared effective by the U.S. Securities and Exchange Commission (the “SEC”), and the approval by Nasdaq of the listing application of the combined company. The Business Combination is expected to be completed by the fourth quarter of 2025. Celine & Partners, PLLC acted as legal advisor for Black Hawk Acquisition Corporation. Ogier Global Limited acted as legal advisor for Black Hawk Acquisition Corporation. PW Richter plc acted as legal advisor for Vesicor Therapeutics, Inc.